Elevated KRAS protein level is associated with better survival in pancreatic cancer
Abstract Background Activating somatic KRAS mutations in hotspot loci occur almost universally (> 95%) in pancreatic ductal adenocarcinoma (PDAC). Both the presence of a KRAS mutation and high mRNA expression levels of KRAS in tumor tissue have been associated with worse outcome. Less is known ab...
Saved in:
| Main Authors: | S. M. Stålberg, L. Silwal-Pandit, J. Hamfjord, D. J. H. Nebdal, J. Lehtiö, O. C. Lingjærde, B. S. Skålhegg, E. H. Kure |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14461-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
by: Mahmoud Yousef, et al.
Published: (2025-04-01) -
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01) -
Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-07-01) -
The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01) -
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
by: Eszter Molnár, et al.
Published: (2024-12-01)